Lung-on-chip provides new insight on body's response to early tuberculosis infection

November 24, 2020

Scientists have developed a lung-on-chip model to study how the body responds to early tuberculosis (TB) infection, according to findings published today in eLife.

TB is a disease caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis) and most often affects the lungs. The model reveals that respiratory system cells, called alveolar epithelial cells, play an essential role in controlling early TB infection. They do this by producing a substance called surfactant - a mixture of molecules (lipids and proteins) that reduce the surface tension where air and liquid meet in the lung.

These findings add to our understanding of what happens during early TB infection, and may explain in part why those who smoke or have compromised surfactant functionality have a higher risk of contracting primary or recurrent infection.

TB is one of the world's top infectious killers and affects people of all ages. While it mostly affects adults, there are currently no effective vaccines available to this group. This is partly due to challenges with studying the early stages of infection, which take place when just one or two M. tuberculosis bacteria are deposited deep inside the lung.

"We created the lung-on-chip model as a way of studying some of these early events," explains lead author Vivek Thacker, a postdoctoral researcher at the McKinney Lab, École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland. "Previous studies have shown that components of surfactant produced by alveolar epithelial cells can impair bacterial growth, but that the alveolar epithelial cells themselves can allow intracellular bacterial growth. The roles of these cells in early infection are therefore not completely understood.

"We used our model to observe where the sites of first contact are, how M. tuberculosis grows in alveolar epithelial cells compared to bacteria-killing cells called macrophages, and how the production of surfactant affects growth, all while maintaining these cells at the air-liquid interface found in the lung."

The team used their lung-on-chip model to recreate a deficiency in surfactant produced by alveolar epithelial cells and then see how the lung cells respond to early TB infection. The technology is optically transparent, meaning they could use an imaging technique called time-lapse microscopy to follow the growth of single M. tuberculosis bacteria in either macrophages or alveolar epithelial cells over multiple days.

Their studies revealed that a lack of surfactant results in uncontrolled and rapid bacterial growth in both macrophages and alveolar epithelial cells. On the other hand, the presence of surfactant significantly reduces this growth in both cells and, in some cases, prevents it altogether.

"Our work shines a light on the early events that take place during TB infection and provides a model for scientists to build on for future research into other respiratory infections," says senior author John McKinney, Head of the Laboratory of Microbiology and Microtechnology at EPFL. "It also paves the way for experiments that increase the complexity of our model to help understand why some TB lesions progress while others heal, which can occur at the same time in the same patient. This knowledge could one day be harnessed to develop effective new interventions against TB and other diseases."

The authors add that they are currently using a human lung-on-chip model to study how our lungs may respond to a low-dose infection and inoculation of SARS-CoV-2, the virus that causes COVID-19.
-end-
Reference

The paper 'A lung-on-chip model of early M. tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth' can be freely accessed online at https://doi.org/10.7554/eLife.59961. Contents, including text, figures and data, are free to reuse under a CC BY 4.0 license.

This study was originally posted on the preprint server bioRxiv, at https://www.biorxiv.org/content/10.1101/2020.02.03.931170v2.

Author contact

Vivek Thacker, postdoctoral researcher at EPFL
Email: vivek.thacker@epfl.ch
Twitter:
Media contact

Emily Packer, Media Relations Manager
eLife
e.packer@elifesciences.org
01223 855373

About eLife

eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We work across three major areas: publishing, technology and research culture. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Microbiology and Infectious Disease, and the Physics of Living Systems, while exploring creative new ways to improve how research is assessed and published. We also invest in open-source technology innovation to modernise the infrastructure for science publishing and improve online tools for sharing, using and interacting with new results. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.

To read the latest Microbiology and Infectious Disease research published in eLife, visit https://elifesciences.org/subjects/microbiology-infectious-disease.

And for the latest in the Physics of Living Systems, see https://elifesciences.org/subjects/physics-living-systems.

eLife

Related Tuberculosis Articles from Brightsurf:

Scientists find new way to kill tuberculosis
Scientists have discovered a new way of killing the bacteria that cause tuberculosis (TB), using a toxin produced by the germ itself.

Blocking the iron transport could stop tuberculosis
The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply.

Tuberculosis: New insights into the pathogen
Researchers at the University of W├╝rzburg and the Spanish Cancer Research Centre have gained new insights into the pathogen that causes tuberculosis.

Unmasking the hidden burden of tuberculosis in Mozambique
The real burden of tuberculosis is probably higher than estimated, according to a study on samples from autopsies performed in a Mozambican hospital.

HIV/tuberculosis co-infection: Tunneling towards better diagnosis
1.2 million people in the world are co-infected by the bacteria which causes tuberculosis and AIDS.

Reducing the burden of tuberculosis treatment
A research team led by MIT has developed a device that can lodge in the stomach and deliver antibiotics to treat tuberculosis, which they hope will make it easier to cure more patients and reduce health care costs.

Tuberculosis: Commandeering a bacterial 'suicide' mechanism
The bacteria responsible for tuberculosis can be killed by a toxin they produce unless it is neutralized by an antidote protein.

A copper bullet for tuberculosis
Tuberculosis is a sneaky disease, and the number one cause of death from infectious disease worldwide.

How damaging immune cells develop during tuberculosis
Insights into how harmful white blood cells form during tuberculosis infection point to novel targets for pharmacological interventions, according to a study published in the open-access journal PLOS Pathogens by Valentina Guerrini and Maria Laura Gennaro of Rutgers New Jersey Medical School, and colleagues.

How many people die from tuberculosis every year?
The estimates for global tuberculosis deaths by the World Health Organisation (WHO) and the Institute for Health Metrics and Evaluation (IHME) differ considerably for a dozen countries, according to a study led by ISGlobal.

Read More: Tuberculosis News and Tuberculosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.